Profile data is unavailable for this security.
About the company
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.
- Revenue in HKD (TTM)87.82m
- Net income in HKD-799.16m
- Incorporated2018
- Employees1.12k
- LocationKeyMed Biosciences Inc18 Biotown Middle Road Building D2Chengdu Tianfu International BiotownCHENGDU 610219ChinaCHN
- Websitehttps://www.keymedbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mesoblast Ltd | 45.59m | -679.38m | 8.79bn | 73.00 | -- | 2.37 | -- | 192.74 | -0.1341 | -0.1341 | 0.0092 | 0.6443 | 0.0088 | -- | 3.21 | 123,755.20 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
| TYK Medicines Inc | 0.00 | -460.24m | 9.09bn | 144.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -3.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -50.25 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
| Polaris Group LLC | 15.70m | -457.77m | 9.49bn | -- | -- | 5.58 | -- | 604.16 | -2.57 | -2.57 | 0.088 | 9.21 | 0.007 | -- | 33.03 | -- | -20.88 | -16.55 | -22.66 | -17.96 | -19.17 | -- | -2,973.29 | -12,960.21 | 9.74 | -- | 0.2065 | -- | 16.18 | -- | -37.05 | -- | 50.45 | -- |
| Bio-Thera Solutions Ltd | 888.58m | -406.69m | 10.59bn | 1.17k | -- | 11.61 | -- | 11.92 | -0.9121 | -0.9121 | 1.99 | 2.05 | 0.3533 | 1.00 | 6.83 | 707,092.40 | -16.17 | -23.62 | -26.76 | -30.81 | 69.81 | 79.76 | -45.77 | -106.72 | 0.716 | -27.47 | 0.4531 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 182.44m | -1.16bn | 10.76bn | 1.40k | -- | 5.21 | -- | 58.97 | -2.69 | -2.69 | 0.424 | 4.80 | 0.0379 | 0.089 | 9.74 | 113,628.50 | -24.10 | -37.61 | -30.74 | -45.95 | 90.50 | 81.54 | -636.41 | -2,112.26 | 1.25 | -41.98 | 0.5339 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -213.58m | 11.41bn | -- | -- | 15.04 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
| Keymed Biosciences Inc | 87.82m | -799.16m | 11.58bn | 1.12k | -- | 4.08 | -- | 131.88 | -3.06 | -3.06 | 0.3359 | 10.14 | 0.0207 | 0.3115 | 7.74 | 97,900.21 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Ascentage Pharma Group International | 971.19m | -387.48m | 12.94bn | 574.00 | -- | 15.67 | -- | 13.32 | -1.34 | -1.34 | 3.34 | 2.62 | 0.2998 | 3.49 | 2.19 | 1,665,855.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| Joinn Laboratories China Co Ltd | 2.29bn | -983.00k | 14.28bn | 2.59k | -- | 1.81 | -- | 6.24 | -0.0064 | -0.0064 | 2.82 | 10.68 | 0.2151 | 0.7714 | 7.32 | -- | -0.09 | 8.99 | -0.106 | 11.07 | 31.83 | 46.76 | -0.4184 | 32.01 | 2.85 | 1.25 | 0.0089 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| InnoCare Pharma Ltd | 967.99m | -404.36m | 14.37bn | 1.09k | -- | 3.46 | -- | 14.85 | -0.2325 | -0.2325 | 0.537 | 3.86 | 0.0922 | 1.32 | 3.73 | 825,457.90 | -4.02 | -- | -4.78 | -- | 84.50 | -- | -43.57 | -- | 7.65 | -- | 0.1547 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
Data as of Nov 14 2024. Currency figures normalised to KeyMed Biosciences Inc's reporting currency: Hong Kong Dollar HKD
16.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 7.63m | 2.73% |
| HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 2024 | 7.31m | 2.61% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 6.91m | 2.47% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 5.70m | 2.04% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 4.64m | 1.66% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2024 | 4.62m | 1.65% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.55m | 0.91% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.43m | 0.87% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 2.13m | 0.76% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 1.96m | 0.70% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
